SCHEMBL6705352

SCHEMBL6705352

CCCCCCCCCCOc1ccc(C(O)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.54
NR5A1 Q13285 1/20 0.51
TP53 P04637 1/20 0.50
TSHR P16473 1/20 0.50
PLA2G4B P0C869 1/20 0.49
DRD2 P14416 2/20 0.48
DRD3 P35462 2/20 0.48
MLNR O43193 1/20 0.48
NR1I2 O75469 1/20 0.48
ESR1 P03372 1/20 0.48
NR3C1 P04150 1/20 0.48
PGR P06401 1/20 0.48
ADRB2 P07550 1/20 0.48
CHRM2 P08172 1/20 0.48
ADRB1 P08588 1/20 0.48
HTR1A P08908 1/20 0.48
ADRA2A P08913 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
CHRM1 P11229 1/20 0.48
ADRA2B P18089 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18302086 0.94 LTA4H (0.60) LTA4HNR5A1TP53TSHRPLA2G4B
SCHEMBL18302066 0.94 NR5A1 (0.57) LTA4HNR5A1TP53TSHRPLA2G4B
SCHEMBL533827 0.94 LTA4H (0.60) LTA4HNR5A1TP53TSHRPLA2G4B
SCHEMBL9304869 0.94 LTA4H (0.60) LTA4HNR5A1TP53TSHRPLA2G4B
SCHEMBL21103504 0.87 LTA4H (0.58) LTA4HNR5A1TP53TSHRPLA2G4B
SCHEMBL6437472 0.85 PPARA (0.55) PLA2G4BALDH1A1CYP3A4SMN1; SMN2
SCHEMBL3862420 0.84 KIF11 (0.60) DRD2DRD3ESR1KCNH2ALDH1A1
SCHEMBL18387604 0.83 ACSS2 (0.50) LTA4HKCNH2ALDH1A1LMNAMAPK1
Anisole SCHEMBL28183591 0.83 LTA4H (0.70) LTA4HNR5A1TP53TSHRDRD2
Anisole SCHEMBL28183589 0.83 LTA4H (0.70) LTA4HNR5A1TP53TSHRDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040116685-A1 Method for solution phase synthesis of oligonucleotides PROLIGO LLC 2004-06-17 US disclosed
EP-0996627-A4 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES AND PEPTIDES PROLIGO L L C (US) 2002-01-02 EP disclosed
US-6262251-B1 PRODUCT ANCHORED SEQUENCIAL SYNTHESIS (PASS); AN ANCHOR GROUP ATTACHED TO THE 5' END OF THE GROWING OLIGONUCLEOTIDE PRODUCT ALLOWS THE COUPLED PRODUCT TO BE SEPARATED FROM UNREACTED STARTING MATERIALS PROLIGO LLC 2001-07-17 US disclosed
EP-0979233-A4 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES PROLIGO L L C (US) 2001-03-21 EP disclosed
EP-0996627-A1 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES AND PEPTIDES Proligo L.L.C. (US) 2000-05-03 EP disclosed
EP-0979233-A1 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES NeXstar Pharmaceuticals, Inc. (US) 2000-02-16 EP disclosed
US-6001966-A REACTING N-TERMINAL PROTECTED AMINO ACID WITH PEPTIDE STARTING MATERIAL FORMING A PEPTIDE PRODUCT, PARTITIONING FROM UNREACTED MATERIAL AND REAGENTS BASED ON PRESENCE OF N-TERMINAL BLOCKING/ANCHORING GROUP PROLIGO LLC (US) 1999-12-14 US disclosed
US-5874532-A USING A N-TERMINAL PROTECTED AMINO ACID MONOMER NEXSTAR PHARMACEUTICALS, INC. (US) 1999-02-23 US disclosed
WO-1998047910-A1 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES PROLIGO LLC (US) 1998-10-29 WO disclosed
EP-0863910-A1 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES NeXstar Pharmaceuticals, Inc. (US) 1998-09-16 EP disclosed
WO-1998030578-A1 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES AND PEPTIDES PROLIGO LLC (US) 1998-07-16 WO disclosed
WO-1997014706-A1 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES NEXSTAR PHARMACEUTICALS, INC. (US) 1997-04-24 WO disclosed